606 results about "Myocardial cell" patented technology

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention relates to application of an MYZAP overexpression vector in preparation of a medicine for preventing and treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problem that application of gene drugs in prevention and treatment of myocardial ischemia reperfusion injury is limited, the invention provides application of an MYZAP gene overexpression recombinant vector in preparation of drugs for prevention and treatment of myocardial ischemia reperfusion injury, and the MYZAP gene overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP for overexpressing MYZAP. Experiments prove that MYZAP overexpression can improve the cardiac function after myocardial ischemia reperfusion, reduce the occurrence rate of arrhythmia and improve the functions of sodium ion channels, potassium ion channels and calcium ion channels of myocardial cells. On the basis, the invention further provides a medicine for preventing and treating myocardial ischemia reperfusion injury, a new strategy is provided for gene therapy of myocardial ischemia reperfusion injury, and the medicine has a wide clinical application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition for resisting doxorubicin cardiotoxicity and a preparation method, application and a preparation thereof. The invention provides a composition capable of resisting doxorubicin cardiotoxicity, the composition comprises diosmetin and loureirin B, the diosmetin and the loureirin B can be extracted through natural plants, the raw materials are low in cost and easy to obtain, and clinical popularization and application are facilitated. The cell experiment research finds that the combined administration of diosmetin and loureirin B can significantly improve the survival rate of adriamycin-damaged myocardial cells and significantly reduce the active oxygen level and positive cell rate, and verifies the synergistic interaction of diosmetin and loureirin B in resisting adriamycin cardiotoxicity.

The invention belongs to the field of medicines, and relates to a compound derived from Sinkiang lithospermum, a preparation method thereof and application of the compound in prevention and treatment of cardiovascular diseases. Specifically, the invention discloses a monoterpene benzoquinone derivative with a novel structure in Sinkiang lithospermum, a preparation method of the monoterpene benzoquinone derivative and application of the compound in preparation of anti-myocardial injury drugs. An in-vitro anti-myocardial cell injury activity experiment proves that the compound has a remarkable protection effect on isoprenaline (ISO)-induced H9C2 cell (rat embryo myocardial cell) injury and hypoxia-reoxygenation-induced H9C2 myocardial cell injury. The result shows that the compound can be used for preparing the anti-cardiovascular disease medicine.

The invention provides a dilated cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology.The dilated cardiomyopathy zebrafish model is constructed by overexpressing miR-16-5p in myocardial cells of zebrafish, and the sequence of miR-16-5p is shown as SEQ ID NO.1; the invention further provides a construction method of the dilated cardiomyopathy zebra fish model. The invention constructs the dilated cardiomyopathy zebrafish model of overexpression miR-16-5p in myocardial cells for the first time, and the dilated cardiomyopathy zebrafish model can be used for screening drugs for resisting dilated cardiomyopathy.

The invention relates to the technical field of traditional Chinese medicine carbon dots, in particular to ligusticum wallichii carbon dots, a medicine and application. The ligusticum wallichii carbon dots disclosed by the invention are obtained by carbonizing ligusticum wallichii by a hydrothermal method, wherein the hydrothermal method carbonization is a hydrothermal reaction at 175-195 DEG C for 8-12 hours; research finds that the ligusticum wallichii carbon dots have the characteristic of treating myocardial apoptosis caused by myocardial ischemia reperfusion injury, and compared with ligusticum wallichii carbon dots synthesized by ligustrazine and a pyrolysis method, the ligusticum wallichii carbon dots have the advantage that the heart function can be better recovered. The invention provides a new candidate drug for treating myocardial ischemia reperfusion injury.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

Disclosed in the present invention is a use of alisol-B23-acetate (AB23a) in the preparation of a drug for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. The present invention provides for the first time a use of AB23a in the prevention or treatment of hypertrophic cardiomyopathy. According to the present invention, use of AB23a in direct in vitro treatment of cardiomyocytes derived from directed differentiation of human embryonic stem cells revealed that AB23a-based in-vitro treatment can significantly inhibit hypertrophic phenotypes of the human embryonic stem cells-cardiomyocytes; using an AB23a-containing feed to feed mice with hereditary hypertrophic cardiomyopathy caused by a gene mutation revealed that AB23a prominently relieves pathological myocardial hypertrophy of the mice and improves the cardiac function; AB23a can be used for preparing a drug for resisting hereditary hypertrophic cardiomyopathy, offering a novel way and means for treating hypertrophic cardiomyopathy; and AB23a is the main medicinal ingredient in the traditional Chinese medicinal herb-Rhizoma Alismatis, is safe to organisms, and has good clinical application prospects.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses a medicine prepared from apoptotic fibroblast-derived vesicles and used for preventing and treating myocardial ischemia-reperfusion injury as well as a preparation method and application of the medicine, and relates to the technical field of biological medicines. The method comprises the following steps: digesting an in-vitro animal heart apex tissue to obtain a digested cell suspension; the myocardial fibroblasts are obtained; the method comprises the following steps: culturing myocardial fibroblasts in a DMEM (dulbecco's modified eagle medium) solution through apoptosis inducer H2O2 to obtain a culture solution; according to the method, apoptosis of fibroblasts is induced to generate specific extracellular vesicles, the surface of the extracellular vesicles carries CD22 as a marker, the content of the extracellular vesicles is enriched in miR-1246 and is taken by myocardial cells, expression of p53 is down-regulated, mitochondrial homeostasis is maintained, and the extracellular vesicles can be used for detecting apoptosis of the fibroblasts. The myocardial cell apoptosis is inhibited.

The invention provides a construction method and application of a dilated cardiomyopathy animal model, belongs to the technical field of biological medicine and animal genetic model construction, and provides a novel dilated cardiomyopathy zebrafish model which is constructed by specifically overexpressing a truncated dnajb6b gene long isomer fragment in zebrafish myocardial cells. The nucleotide sequence of the gene segment is as shown in SEQ ID NO. 1; the invention also provides a construction method and application of the dilated cardiomyopathy zebra fish model, and further discovers application of 4-phenylbutyric acid in preparation of drugs for treating dilated cardiomyopathy.

The invention provides a hypertrophic cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology, the hypertrophic cardiomyopathy zebrafish model is constructed by overexpressing miR-29a in myocardial cells of zebrafish, and the sequence of the miR-29a is shown as SEQ ID NO.1; the invention further provides a construction method of the hypertrophic cardiomyopathy zebra fish model. The hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) with overexpression of miR-29a in myocardial cells is constructed for the first time, and the hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) can be used for screening drugs for resisting hypertrophic cardiomyopathy.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The application relates to a rotary cutting type myocardial biopsy forceps, which comprises a sleeve assembly, a catheter and a handle assembly, the distal end of the handle assembly is connected with the proximal end of the catheter, and the distal end of the catheter is connected with the sleeve assembly; the sleeve assembly comprises a sleeve body, the proximal end of the sleeve body is connected with the catheter, the distal end of the sleeve body is provided with an open port, the inside of the sleeve body is slidably provided with a rotary cutting knife, the inside of the catheter is provided with a first driving member, the handle assembly is drivingly connected with the rotary cutting knife through the first driving member, so as to drive the rotary cutting knife to extend out of the sleeve body and cut myocardial tissue; the distal end of the sleeve body is movably provided with a closing assembly, the inside of the catheter is provided with a second driving member, the handle assembly is drivingly connected with the closing assembly through the second driving member, so as to control the closing assembly to selectively open or close the open port at the distal end of the sleeve body. The rotary cutting type myocardial biopsy forceps can accurately control the sampling depth, and the open port at the distal end of the sleeve body can be closed after sampling, so that myocardial cells are prevented from falling off.

The invention belongs to the technical field of cell electrophysiological signal recognition, and discloses a cell electrophysiological signal recognition method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining an original electrophysiological signal of a myocardial cell, mechanical data of the action of a mechanical probe and the myocardial cell, and illumination parameters of an optical imaging system, the method comprises the following steps: acquiring an original electrophysiological signal, identifying from the original electrophysiological signal to obtain a mechanical artifact signal associated with mechanical data, determining instantaneous mechanical stiffness of myocardial cells based on the mechanical artifact signal so as to identify and obtain a pulsation stage in which the myocardial cells are currently located, and calculating to obtain a photo-thermal artifact signal in the original electrophysiological signal according to the pulsation stage and illumination parameters, separating a mechanical artifact signal and a photo-thermal artifact signal from the original electrophysiological signal to obtain a real electrophysiological signal of the myocardial cell; by means of the method, the electrophysiological signal recognition accuracy of the myocardial cells is improved.

The invention discloses a method for high-throughput preparation of heart organoid. Relates to the technical field of biology. Comprising the following steps: culturing iPSC; performing iPSC digestion, inoculation and culture before induction; performing induction; and continuously culturing. The method can be used for simply preparing a large number of heart organs. The preparation method is simple and convenient, has low requirements on materials and equipment, and needs few reagents. And a large number of organoid can be obtained in the same batch. The organoid is composed of various cell types such as myocardial cells, fibroblasts, vascular endothelial cells and the like. The contraction of the cardiac organoids is induced in response to a drug.

The rotary cutting type myocardial biopsy forceps comprise a sleeve assembly, a catheter and a handle assembly, the far end of the handle assembly is connected with the near end of the catheter, and the far end of the catheter is connected with the sleeve assembly; the sleeve assembly comprises a sleeve body, the near end of the sleeve body is connected with the catheter, the far end of the sleeve body is provided with an opening, a rotary cutter is slidably arranged in the sleeve body, a first driving part is arranged in the catheter, and the handle assembly is in driving connection with the rotary cutter through the first driving part and used for driving the rotary cutter to stretch out of the sleeve body. The cardiac muscle tissue is subjected to rotary cutting; a closing assembly is movably arranged at the far end of the sleeve body, a second driving part is arranged in the catheter, and the handle assembly is in driving connection with the closing assembly through the second driving part and used for controlling the closing assembly to selectively open or close an opening in the far end of the sleeve body. The rotary cutting type myocardial biopsy forceps can accurately control the sampling depth, and the opening in the far end of the sleeve body can be closed after sampling, so that myocardial cells are prevented from falling off.

The invention relates to the field of biological extraction, substance analysis, application and effect evaluation, in particular to an extraction method of polysaccharide of an overground part of chicory, the polysaccharide and a related application and evaluation method. The method comprises the following steps: providing an extraction method of the polysaccharide of the overground part of the chicory, carrying out reflux extraction, concentration, precipitation, centrifugation, washing and freeze-drying to obtain the polysaccharide, and carrying out molecular weight distribution and monosaccharide composition analysis on the polysaccharide, and the polysaccharide has antioxidant and anti-inflammatory activity, can be used for preparing products for protecting myocardial cells and the like, and has wide application prospects. The invention also discloses a composition containing the polysaccharide and an evaluation method for comparing the myocardial protection activity of the polysaccharide at different parts of the cichorium intybus. The application achieves the technical effects of efficiently extracting the polysaccharide of the overground part of the chicory, determining the characteristics and effects of the polysaccharide, providing a basis for development of products related to cardiovascular disease prevention and treatment, and providing a method for evaluating the myocardial protection activity of the polysaccharide of different parts of the chicory.

The invention relates to the technical field of biological medicines, in particular to a polycyclic polyisopentenyl cyclopentanone compound as well as a preparation method and application thereof. The polycyclic polyisopentenyl cyclopentanone compound provided by the invention has a structural formula as shown in a formula 1; the preparation method comprises the following steps: by taking dry fruits of hypericum berry as raw materials, carrying out percolation extraction and concentration to obtain an extract, suspending the extract in water to obtain a suspension, and extracting and concentrating the suspension with petroleum ether to obtain a crude extract; the crude extract is taken and subjected to positive and negative phase silica gel column separation, MCI medium-pressure column chromatography, Sephadex LH-20 gel column chromatographic separation, high performance liquid chromatography preparation and CHIRALPAK IG chiral column resolution, and the polycyclic polyisopentenyl cyclopentanone compound is obtained. The protection activity of the compound on AC16 myocardial cell injury induced by cold ischemia is evaluated, and the compound can be used for preparing the polycyclic polyisopentenyl cyclopentanone compound. The compounds can be used as lead compounds for developing medicines for preventing and treating myocardial cold ischemia injury.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

A heart organoid of at least 60% cardiac cells irrespective of optional additional cells of a vascular system of the organoid, or including at least 50% cardiac cells; wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from the group of cardiomyocytes, endocardial cells and epicardial cells, and wherein the heart organoid includes cardiomyocytes or endocardial cells that directly face the inner cavity, a method for the generation of such a tissue model and uses thereof.

The invention provides application of a CTSL inhibitor in preparation of a medicine for treating fulminant myocarditis, and particularly belongs to the technical field of biological medicine. It is found that CTSL in cardiac muscle tissue of a mouse with the fulminant myocarditis is remarkably increased, and the CTSL inhibitor can be used for preparing the medicine for treating the fulminant myocarditis. Results show that the CTSL inhibitor can improve myocardial cell injury, cardiac inflammation, rational reconstitution and functions of heart diseases, increase survival rate and realize treatment of fulminating myocarditis.

The present disclosure describes systems and methods for cell therapy. Cells (e.g., stem cells, immune cells, cardiomyocytes, etc.) may be engineered to exhibit extended half-lives as compared to control cells (e.g., non-engineered cells). The cells may be engineered to exhibit increased proliferative activity as compared to control cells. In some embodiments, immune cells may be engineered to efficiently and specifically target diseased cells (e.g., cancer cells) while control cells are insufficient or unable to target the diseased cells. In some embodiments, stem cells or differentiated cells, such as myocardial cells, may be administered to a target tissue for enhanced tissue engineering or regenerative medicine. The engineered cells disclosed herein can be engineered ex vivo, in vitro, and in some embodiments in vivo. Engineered cells prepared ex vivo or in vitro may be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumor). The engineered cell may be autologous to the subject. Alternatively, the engineered cell may also be allogeneic to the subject.

The application provides a sub-threshold heart communication method, system, device, medium and application, and belongs to the technical field of biomedical engineering. The method comprises the following steps: constructing a communication channel formed by coupling of multiple three-dimensional myocardial cell models; modulating physiological information into a sub-threshold electrical signal and injecting the signal into the channel for transmission; demodulating the signal at a receiving end to recover the information; wherein a physiological noise model is integrated in the channel to simulate a real physiological environment. The system corresponds to a transmitting end, a communication channel and a receiving end. The application adopts the sub-threshold heart communication method, system, device, medium and application, the three-dimensional myocardial cell model is used to more truly simulate a heart tissue structure, the complete communication process simulation of the sub-threshold electrical signal in a noise environment is realized for the first time, the existing research gap is filled, and an innovative technical platform is provided for research on cardiac electrophysiological mechanisms, performance optimization and evaluation of implantable medical devices such as a cardiac pacemaker.

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

This invention discloses a cardioprotective compound composition and its preparation based on improving the absorption rate of coenzyme Q10, relating to the fields of pharmaceuticals and functional foods. The core active ingredients of this composition consist of coenzyme Q10, vitamin E, and black pepper extract, with a specific mass ratio range for each. It can also be combined with pharmaceutically acceptable carriers and antioxidant synergists to prepare various oral formulations. This invention, through the construction of a ternary active component with a specific ratio, achieves in vivo synergistic effects on absorption promotion and antioxidant regeneration, solving the technical problems of low oral bioavailability and insufficient accumulation of myocardial-targeted activity in existing coenzyme Q10 preparations. It significantly improves the conversion efficiency of coenzyme Q10 into a usable active form for cardiomyocytes and can be widely applied in the preparation of drugs and functional foods for the prevention or treatment of heart diseases.

The invention discloses construction of myocardial cells differentiated from propionemia stem cells based on a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The model constructed by the invention has the metabolic phenotype of propionemia and can also be differentiated into myocardial cells. A reliable and effective experimental model is provided for research of propionemia disease related targets and screening of drugs for preventing / treating propionemia, and the method has a wide application prospect.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.